Dr. Katabi is a General Partner at Sofinnova Investments. She is an experienced investor with over two decades of managing public and private biotech companies through bull and bear markets. She is focused on investing in development stage biopharmaceuticals and is currently member of the board of directors of Marea, Quanta, and Star. Most recently, Dr. Katabi was a board member of Aiolos (acquired by GSK), RayzeBio (acquired by BMS), Amplyx (acquired by Pfizer), Gyroscope (acquired by Novartis) and Northsea.
Prior to joining Sofinnova in 2019, Maha was Managing Partner of Oxalis Capital. Before founding Oxalis, she was Partner at Sectoral Asset Management, where she formed and led a dedicated investment team and advisory board to drive investments in private companies. These included Ascendis, Apellis, and Trius (acquired by Cubist), which are also Sofinnova portfolio companies. Additionally, she was a Portfolio Manager for a family of funds that invested in small cap healthcare companies. She started her career in venture as a principal investor with associate and principal roles at T²C²/Bio and Ventures West.
Maha received her BSc In Biology and PhD in Pharmacology from McGill University, where she was a Cancer Research Society fellow, and is a CFA charter holder since 2011. She currently serves as Chair of the board of Exactis Innovation, a not-for profit oncology precision medicine network. Fierce Pharma named Dr. Katabi one of 2023’s Fiercest Women in Life Sciences. She serves as an advisor to amplifyHERscience, a Yale Ventures initiative.
What is Maha Katabi's net worth?
The estimated net worth of Maha Katabi is at least $59.70 million as of March 25th, 2024. Katabi owns 2,793,987 shares of Vera Therapeutics stock worth more than $59,704,708 as of April 17th. This net worth estimate does not reflect any other assets that Katabi may own. Learn More about Maha Katabi's net worth.
How do I contact Maha Katabi?
Has Maha Katabi been buying or selling shares of Vera Therapeutics?
Maha Katabi has not been actively trading shares of Vera Therapeutics over the course of the past ninety days. Most recently, Maha Katabi sold 340,000 shares of the business's stock in a transaction on Monday, March 25th. The shares were sold at an average price of $40.50, for a transaction totalling $13,770,000.00. Following the completion of the sale, the director now directly owns 2,793,987 shares of the company's stock, valued at $113,156,473.50. Learn More on Maha Katabi's trading history.
Who are Vera Therapeutics' active insiders?
Are insiders buying or selling shares of Vera Therapeutics?
In the last year, insiders at the sold shares 10 times. They sold a total of 156,898 shares worth more than $6,681,787.73. The most recent insider tranaction occured on January, 8th when CEO Marshall Fordyce sold 17,500 shares worth more than $730,450.00. Insiders at Vera Therapeutics own 21.7% of the company.
Learn More about insider trades at Vera Therapeutics. Information on this page was last updated on 1/8/2025.
